T he majority of the patients with severe symptomatic mitral regurgitation with concomitant left ventricular dysfunction and previous cardiac surgery do not undergo redo surgery, though it may be recommended in the current guidelines. [1, 2] The off-label use of standard aortic transcatheter heart valves (THV) has emerged as an exciting new frontier in the treatment of a failed mitral bioprosthesis or surgical ring, as well as for patients with severe annular calcification. [3, 4] These platforms provide anchoring for an expandable balloon or the newer aortic THVs. Hundreds of patients worldwide have been treated with a transcatheter mitral valve-in-ring or valve-in-valve procedure using a bioprosthetic aortic valve. [5, 6] A Sapien valve (Edwards Lifesciences; Irvine, CA, USA) has been implanted in the majority of cases. This report is a description of a transseptal mitral valve replacement in a case of a failed surgical bioprosthesis.
CASE REPORT
A 74-year-old woman was referred for evaluation and treatment of severe mitral regurgitation. Her history included bioprosthetic aortic replacement with a 27-mm Carpentier-Edwards mitral valve (Edwards Lifesciences; Irvine, CA, USA) replacement 10 years earlier. Two years after the surgery, she underwent percutaneous mitral paravalvular leak closure. Echocardiography revealed severe transvalvular mitral regur-gitation, an estimated left ventricular (LV) ejection fraction of 0.45, and a pulmonary arterial systolic pressure of 60 mm Hg. Since the patient was highly symptomatic and was not a good candidate for surgery, percutaneous mitral valve replacement was scheduled.
Evaluation of mitral valve regurgitation was performed using 2-dimensional transesophageal echocardiography (2D-TEE) and valve sizing was determined based on the previous bioprosthetic valve size (Fig.  1a , Video 1 * ). The ideal THV size for the valve-invalve procedure was selected based on the true internal diameter (which determines prosthesis anchoring), which is typically 1 to 2 mm smaller than the diameter of the surgical valve size reported by the manufacturer. The commercially available Mitral V-in-V smartphone application, designed by Vinayak Bapat, [7] was also used to verify the ideal valve size. The procedures were performed with general anesthesia, and percutaneous femoral venous access was used. After a transseptal puncture in the inferoposterior portion of the fossa ovalis with 2D-TEE and flouroscopic guidance using a transfemoral approach, balloon dilatation (12-mm x 60-mm) of the septum was performed to facilitate the crossing of the septum (Fig. 1b) . The transseptal sheath and dilator were advanced over a 0.035-inch J guidewire under fluoroscopy guidance into the left atrium. A soft, straight-tip, 0.032-inch wire, which was positioned using a deflectable left atrial sheath (Agilis NxT steerable introducer; St Jude Medical, St. Paul, MN, USA) was advanced through the mitral prosthesis (Fig. 1c , Video 2 * ). Two Amplatz Super Stiff guidewires and a Safari wire (Boston Scientific Corp., Marlborough, MA, USA) were placed through a pigtail catheter in the left ventricular apex after removing the straight-tip wire. Movement during deployment was minimized with coaxial guidewires without pacing or apnea, and the second wire outside the THV delivery system was pulled back preceding deployment of the valve. The ventricular edge of a Sapien-XT stent frame was positioned at the ventricular edge of the pre-existing bioprosthesis. The 26-mm Sapien-XT valve was slowly mounted in the opposite direction to the transfemoral aortic THV within the (Fig 1d, Video 3 * ). TEE demonstrated complete resolution of mitral regurgitation (Video 4 * ) and the transvalvular mean gradient across the mitral prosthesis was measured as 4 mm Hg. The patient was discharged from on day 2 with a New York Heart Association functional class II designation and daily use of clopidogrel 75 mg and aspirin 100 was initiated.
DISCUSSION
Transcatheter mitral valve replacement has been performed for patients with a regurgitant mitral valve, a failing mitral valve bioprosthetic or ring, or a calcified mitral annulus, since these patients may have multiple comorbidities, an increased risk of operative mortality, and an extended hospital stay. [8] The data regarding implantation of an aortic THV within a degenerated bioprosthetic mitral valve (valve-in-valve) or a mitral valve ring (valve-in-ring) is generally limited to case series using the Edwards Sapien series, the Boston Scientific Lotus valves, the Medtronic Melody products (Medtronic Inc., Minneapolis, MN, USA), and Direct Flow Medical valves (Direct Flow Medical Inc, Santa Rosa, CA, USA) with no long-term results. [9] The anatomical challenges associated with mitral THV implantation have been clearly defined: the valve system must be delivered to, anchored, and sealed within a large, non-circular, saddle-shaped, highly dynamic, and sometimes calcific annulus to overcome the loading conditions of the LV. The complex, highly individualized, subvalvular apparatus and the mitral annulus proximal to the left ventricular outflow tract (LVOT), the coronary sinus, and the left circumflex coronary artery pose a risk for impingement. [10] These anatomical challenges have delayed mitral THV development. Malposition, paravalvular leak, embolization, LVOT obstruction, leaflet thrombosis, hemolysis, aortic valve injury, reduced ejection fraction, limited large transcatheter aortic valve size, and stroke are possible complications of mitral THV replacement.
A venous access procedure was performed in our case while avoiding the potential complications of bleeding, apical injury, and lung injury due to thoracotomy, as well as a long hospital stay. The standard surgical approach for a mitral valve replacement is via a left atriotomy; however, a transseptal surgical approach via a right atriotomy has been preferred for patients with a small left atrium, friable tissues, heavily calcified mitral valves, or when there is the need to perform combined tricuspid and mitral procedures. [10] In our patient, the previous left atriotomy made a transseptal approach easier. A transapical approach might be preferred to a transseptal alternative, as it enables greater control of the delivery system, but it is more invasive. A single-center report found that among 24 patients who underwent a mitral transcatheter valve-in-valve procedure, the patients treated with a transseptal approach had a significant increase in cardiac output and improved survival when compared with patients treated with a transapical approach. [11] Our patient recovered quickly and was discharged on the second day after the procedure.
Another important factor contributing to successful valve-in-valve implantation is comprehensive understanding of the dimensions listed by the manufacturer or the Mitral V-in-V smartphone application, the measurements obtained from the CT scan, the type of valve pathology (stenosis or regurgitation), and the risk of LVOT obstruction. [12, 13] Since a stented surgical bioprosthesis provides good surgical landmarks, and an appropriate semirigid and circular landing zone is selected easily under fluoroscopic guidance, we did not perform CT before the intervention. The size of the THV should be sufficiently greater than the internal diameter of the implanted prosthesis for it to be anchored inside the previous stent. There is a high risk of embolization or atrial migration with an undersized valve, and significant oversizing may result in distortion of the transcatheter valve leaflets.
To our knowledge, this is a rare case of successful transcatheter valve-in-valve implantation for a failed prosthetic mitral valve, an off-label use in Turkey. This less invasive therapy may be an alternative or even a better method than surgery in selected cases. Long-term clinical trials are required to confirm the efficacy and safety.
Conclusion
Despite being primarily designed as a valve for the aortic position and the lack of clearly defined longterm valve outcomes, a transcatheter aortic valve used in reverse position for mitral valve-in-valve implantation is an option for patients with failed mitral prosthetic valve dysfunction who are at high risk for surgical valve replacement.
*Supplementary video file associated with this article can be found in the online version of the journal.
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